Evidence map›Paper›PMID 26855766›Full record

ArticleCell & bioscience2016

A novel class of copper(II)- and zinc(II)-bound non-steroidal anti-inflammatory drugs that inhibits acute inflammation in vivo.

Rajesh Puranik, Shisan Bao, Antonio M Bonin, Ravinder Kaur, Jane E Weder, Llewellyn Casbolt, Trevor W Hambley, Peter A Lay, Philip J Barter, Kerry-Anne Rye

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Cell & bioscience, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
5.5field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed, 30 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. CuFrontiers in neuroscience · 2018
    Article
  5. Treatment strategies in Alzheimer's disease: a review with focus on selenium supplementation.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2016
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 3 institutions in 1 country.

Rajesh PuranikThe Heart Research Institute, 7, Eliza St., Sydney, NSW 2042 Australia ; Department of Cardiology, Royal Prince Alfred Hospital, Missenden Rd, Camperdown, NSW 2050 Australia.
Shisan BaoThe Heart Research Institute, 7, Eliza St., Sydney, NSW 2042 Australia ; Discipline of Pathology, D17, The School of Medical Sciences and Bosch Institute, The University of Sydney, Sydney, NSW 2006 Australia.
Antonio M BoninThe School of Chemistry, The University of Sydney, Sydney, NSW 2006 Australia.
Ravinder KaurThe School of Chemistry, The University of Sydney, Sydney, NSW 2006 Australia.
Jane E WederThe School of Chemistry, The University of Sydney, Sydney, NSW 2006 Australia.
Llewellyn CasboltCasbolt & Associates Pty Ltd, Sydney, Australia.
Trevor W HambleyThe School of Chemistry, The University of Sydney, Sydney, NSW 2006 Australia.
Peter A LayThe School of Chemistry, The University of Sydney, Sydney, NSW 2006 Australia.
Philip J BarterThe Heart Research Institute, 7, Eliza St., Sydney, NSW 2042 Australia.
Kerry-Anne RyeThe Heart Research Institute, 7, Eliza St., Sydney, NSW 2042 Australia ; Lipid Research Group, Centre for Vascular Research, The University of New South Wales, Sydney, NSW 2052 Australia.
University of Sydney · AUThe Heart Research Institute · AUUNSW Sydney · AU

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundThe ability of Zn(II) and Cu(II) metal complexes of non-steroidal anti-inflammatory drugs (NSAIDs) to inhibit acute arterial inflammation in vivo has been studied.

resultsWhen acute vascular inflammation was induced in normocholesterolemic New Zealand White rabbits by inserting a non-occlusive silastic collar around the common carotid artery, a single oral dose of Cu(II)-indomethacin (Cu(II)Indo, 3 mg/kg) administered by laparotomy achieved a 67 % (8.2 ± 1.7 vs. 2.7 ± 0.4 image units, p < 0.05) reduction in endothelial expression of vascular cell adhesion molecule-1 (VCAM-1) but did not inhibit endothelial intercellular adhesion molecule (ICAM-1) expression significantly. Treatment with Cu(II)-acemetacin (Cu(II)ACM, 3 mg/kg) led to a profound 88 % (8.2 ± 1.7 vs. 1.0 ± 0.5 image units, p < 0.01) reduction in endothelial VCAM-1 expression but did not inhibit ICAM-1 expression, while treatment with Zn(II)-acemetacin (Zn(II)ACM, 3 mg/kg) led to an 84 % (19.3 ± 1.0 vs. 3.1 ± 1.2 image units, p < 0.01) reduction in endothelial ICAM-1 expression and did not inhibit VCAM-1 expression. No adverse gastric, hepatic or renal effects were observed in treated animals.

conclusionThese findings provide the "proof of concept" that this novel class of drug, where there is complexation of NSAIDs with metal ions, has substantial anti-inflammatory effects in an animal model of acute vascular inflammation with the possibility of low rates of adverse effects.

Indexed as

Copper(II) ACMCopper(II) indomethacinIndomethacinNSAIDsZinc(II) ACM

Identifiers

PMID26855766
PMCPMC4744413
OpenAlexW2299926387

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.